Other News To Note
Wednesday, June 15, 2011
Pacira Pharmaceuticals Inc., of Parsippany, N.J., reported that the FDA extended the PDUFA date for its review of the new drug application for Exparel (bupivacaine extended-release liposome injection), for postoperative analgesia by infiltration, by three months to Oct. 28. The company said it submitted additional information requested by the FDA, which determined that the information constituted a major amendment.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.